Hans van Houte Biography and Net Worth

CFO of Nurix Therapeutics

Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company’s finance team since 2015. Mr. van Houte began his biotechnology finance career as Controller, Treasurer, and Principal Accounting Officer at Vertex Pharmaceuticals, where he helped build the financial and accounting organization post-IPO to support growth from a $100 million to a multibillion market capitalization. Mr. van Houte previously held senior financial roles in biotechnology companies including Vice President, Finance and Operations at Trubion Pharmaceuticals, Inc., where he was part of the team that took Trubion public in October 2006. Prior to joining Nurix, Mr. van Houte was a managing partner at Bionation LLC, a financial consulting firm, and served as acting CFO for multiple new biotechnology companies formed with investments totaling over $150 million from Third Rock Ventures and The Column Group. Mr. van Houte holds a B.S. in Business Administration, Finance and Accounting from Babson College.

What is Hans van Houte's net worth?: The estimated net worth of Hans van Houte is at least $355,282.34 as of May 2nd, 2025. Mr. van Houte owns 33,724 shares of Nurix Therapeutics stock worth more than $355,282 as of May 6th. This net worth estimate does not reflect any other investments that Mr. van Houte may own. Learn More about Hans van Houte's net worth.
How do I contact Hans van Houte?: The corporate mailing address for Mr. van Houte and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at wolffe@wheelhouselsa.com. Learn More on Hans van Houte's contact information.
Has Hans van Houte been buying or selling shares of Nurix Therapeutics?: During the last ninety days, Hans van Houte has sold $98,260.34 in shares of Nurix Therapeutics stock. Most recently, Houte Hans Van sold 6,198 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a transaction totalling $70,223.34. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at $382,092.92. Learn More on Hans van Houte's trading history.
Who are Nurix Therapeutics' active insiders?: Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), Christine Ring (General Counsel), and Hans van Houte (CFO). Learn More on Nurix Therapeutics' active insiders.
Are insiders buying or selling shares of Nurix Therapeutics?: In the last twelve months, insiders at the sold shares 22 times. They sold a total of 106,451 shares worth more than $2,271,016.49. The most recent insider tranaction occured on May, 2nd when CFO Houte Hans Van sold 6,198 shares worth more than $70,223.34. Insiders at Nurix Therapeutics own 7.4% of the company. Learn More about insider trades at Nurix Therapeutics.
Information on this page was last updated on 5/2/2025.

Hans van Houte Insider Trading History at Nurix Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2025	Sell	6,198	$11.33	$70,223.34	33,724
4/30/2025	Sell	2,438	$11.50	$28,037.00	39,922
3/3/2025	Sell	5,825	$14.49	$84,404.25	33,724
1/30/2025	Sell	2,811	$19.85	$55,798.35	39,549
11/1/2024	Sell	3,546	$24.28	$86,096.88	33,724
10/30/2024	Sell	2,368	$24.30	$57,542.40	37,270
8/26/2024	Sell	20,000	$25.22	$504,400.00	31,002
8/1/2024	Sell	3,477	$21.45	$74,581.65	51,002
7/30/2024	Sell	2,490	$20.67	$51,468.30	54,479
5/2/2024	Sell	3,499	$12.83	$44,892.17	68,333
4/30/2024	Sell	1,387	$12.04	$16,699.48	71,832
2/16/2024	Sell	6,812	$10.02	$68,256.24	68,333
1/30/2024	Sell	1,671	$7.99	$13,351.29	75,145
12/19/2023	Sell	10,906	$10.00	$109,060.00	75,471
10/31/2023	Sell	1,080	$5.20	$5,616.00	86,377
7/31/2023	Sell	1,245	$9.65	$12,014.25	82,571
5/1/2023	Sell	721	$9.88	$7,123.48	78,930
1/30/2023	Sell	924	$11.78	$10,884.72	76,765
10/31/2022	Sell	739	$12.88	$9,518.32	74,803
8/1/2022	Sell	752	$15.67	$11,783.84	72,656
5/2/2022	Sell	697	$11.75	$8,189.75	2,189
2/22/2021	Sell	5,330	$39.93	$212,826.90	1,417

See Full Table

Hans van Houte Buying and Selling Activity at Nurix Therapeutics

Nurix Therapeutics Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Today's Range

Now: $9.65

$9.64

$10.86

50 Day Range

MA: $11.91

$8.81

$15.45

2 Week Range

Now: $9.65

$8.18

$29.56

Volume

680,832 shs

Average Volume

885,983 shs

Market Capitalization

$735.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23